Glass House Brands (GLAS) Change in Receivables (2020 - 2026)
Glass House Brands' (GLAS) quarterly Change in Receivables came in at -$2.1 million in Q1 2026, down 47.19% year-on-year from -$4.0 million in Q1 2025, and down 239.36% on a QoQ basis from $1.5 million in Q4 2025.
Glass House Brands (GLAS) Change in Receivables (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Change in Receivables data on file, last reported at -$2.1 million in Q1 2026.
- On a quarterly basis, Change in Receivables fell 47.19% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$125000.0, a 86.47% increase from a year earlier, with the FY2025 full-year figure at $547000.0, down 63.07% from the prior year.
- Change in Receivables for Q1 2026 stood at -$2.1 million, down from $1.5 million in the prior quarter.
- Over the last five years, Change in Receivables for GLAS reached as high as $5.6 million in Q4 2024 and fell as low as -$4.9 million in Q2 2024.
- Historically, Change in Receivables has averaged $21259.8 across 5 years, with a median of $277000.0 in 2022.
- Across the five-year window, Change in Receivables slumped 2147.95% in 2022 and soared 3267.94% in 2024, its largest moves.
- Year by year, Change in Receivables stood at $842000.0 in 2022, then tumbled by 80.2% to $166719.0 in 2023, then surged by 3267.94% to $5.6 million in 2024, then slumped by 73.21% to $1.5 million in 2025, then slumped by 239.36% to -$2.1 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$2.1 million in Q1 2026, $1.5 million in Q4 2025, and $3.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -38.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Sep 30, 2024 | -251,000.00 |
| Sep 30, 2024 | -251,000.00 |
| Jun 30, 2024 | -4.86 Mn |
| Jun 30, 2024 | -4.86 Mn |
| Mar 31, 2024 | 981,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Dec 31, 2023 | 166,719.00 |
| Dec 31, 2023 | 166,719.00 |